Turbogen director holds options for 30,177 shares
Turbogen Ltd. (TRBG) reported the initial beneficial ownership of securities by director Levy Ethy.
Rhea-AI Filing Summary
Turbogen Ltd. (TRBG) reported the initial beneficial ownership of securities by director Levy Ethy. Ethy holds share options giving the right to buy 30,177 ordinary shares, granted on March 9, 2025, that vest in three equal installments of 33.3% beginning March 9, 2025. As of August 25, 2026, 20,118 options are fully vested and none have been exercised into ordinary shares. The options carry an exercise price of NIS 8.95 per share, which for this report was converted using an exchange rate of NIS 2.994 to USD $1.00, resulting in an exercise price of $2.99 per share. The options are held directly, relate to 30,177 underlying ordinary shares, become exercisable beginning March 29, 2025, and expire on March 9, 2032.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Levy Ethy
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Share option (right to buy) F2, F1 | -- | -- | -- |
Holdings After Transaction:
Share option (right to buy) — 30,177 contracts (Direct)
Footnotes (2)
- F1. A total of 30,177 options were granted on March 9, 2025 and vest in three equal installments of 33.3% beginning March 9, 2025. As of August 25, 2026, 20,118 options are fully vested and none have been exercised into ordinary shares.
- F2. The options were granted with an exercise price of NIS 8.95 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 2.994 to USD $1.00 as of August 24, 2026, resulting in an exercise price of $2.99 per share.
Key Figures
Options granted: 30,177 options
Vested options: 20,118 options
Exercise price (NIS): NIS 8.95 per share
+4 more
7 metrics
Options granted
30,177 options
Total share options granted on March 9, 2025
Vested options
20,118 options
Fully vested as of August 25, 2026
Exercise price (NIS)
NIS 8.95 per share
Original grant exercise price per share
Exercise price (USD)
$2.99 per share
Converted using exchange rate NIS 2.994 to USD $1.00 as of August 24, 2026
Exchange rate
NIS 2.994 to USD $1.00
Rate used to convert the exercise price into U.S. dollars
Underlying ordinary shares
30,177 shares
Ordinary shares underlying the reported options
Option expiration date
March 9, 2032
Expiration date of the share options
Key Terms
Ordinary shares, exercise price, vest, exchange rate, +1 more
5 terms
exercise price financial
"The options were granted with an exercise price of NIS 8.95 per share."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vest financial
"A total of 30,177 options were granted on March 9, 2025 and vest in three equal installments"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
exchange rate financial
"converted into U.S. dollars using an exchange rate of NIS 2.994 to USD $1.00"
Exchange rate is the price of one currency expressed in another—for example, how many euros you receive for one US dollar. It matters to investors because changes in that price alter the reported profits, costs and value of assets for companies and portfolios that operate or hold money across borders; think of it like switching measurement units, where the same item can look bigger or smaller depending on the unit used.
Form 3 regulatory
"For purposes of this Form 3, the exercise price has been converted"
Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.
FAQ
What did director Levy Ethy report on this Form 3 for TRBG?
Levy Ethy reported initial beneficial ownership of share options to acquire 30,177 ordinary shares of Turbogen Ltd., granted on March 9, 2025, held directly and expiring on March 9, 2032. As of August 25, 2026, 20,118 of these options are fully vested and none have been exercised.
How many Turbogen (TRBG) options are vested and unexercised for Levy Ethy?
As of August 25, 2026, 20,118 options held by Levy Ethy are fully vested, and the company states that none have been exercised into ordinary shares.
What is the exercise price of Levy Ethy’s Turbogen (TRBG) options?
The options were granted with an exercise price of NIS 8.95 per share. For this report, Turbogen converted that using an exchange rate of NIS 2.994 to USD $1.00, resulting in an exercise price of $2.99 per share.
When do Levy Ethy’s Turbogen (TRBG) options vest and expire?
The 30,177 options granted on March 9, 2025 vest in three equal installments of 33.3% beginning March 9, 2025. The options relate to ordinary shares and expire on March 9, 2032.
Are any Turbogen (TRBG) options reported under a Rule 10b5-1 plan for Levy Ethy?
The report describes the grant, vesting, and exercise price of 30,177 options held by Levy Ethy but does not state that they are subject to a Rule 10b5-1 trading plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
